The umbrella term for the genital, sexual and urinary symptoms caused by declining estrogen, including vaginal dryness, painful sex, vulvar and vaginal irritation, urinary urgency and frequency, and recurrent urinary tract infections.
Terminology
GSM replaced the older terms vulvovaginal atrophy and atrophic vaginitis, which described only part of the picture and omitted the urinary component.
The change matters clinically because the urinary symptoms, including recurrent infection, respond to the same treatment as the vaginal ones.
What is happening
Vaginal and vulvar tissue becomes thinner, less elastic and less well lubricated. Blood flow to the area reduces. Vaginal pH rises, which alters the local microbiome.
The consequences follow from those changes: dryness, discomfort or pain with sex, itching and burning, changes in discharge and odor, urinary urgency and frequency, and urinary tract infections that recur.
Vulvar changes including thinning and retraction of tissue also form part of GSM.
How GSM differs from other menopause symptoms
Vasomotor symptoms tend to ease over time. GSM typically progresses, because the tissue changes continue while estrogen remains low.
Waiting is therefore a poor strategy for GSM specifically, in a way it is not for some other symptoms.
Treatment options
Vaginal moisturizers are used regularly, several times a week, to improve the condition of the tissue. Lubricants are used at the time of sex to reduce friction. The two do different jobs and can be used together.
Local vaginal estrogen is the treatment with the strongest evidence for GSM. It is applied directly as a cream, tablet or ring and acts locally with only minimal absorption into the bloodstream. This is distinct from systemic hormone therapy, and the distinction is significant for both benefit and risk discussion.
Local vaginal estrogen also has evidence for reducing recurrent urinary tract infections. A suspected active infection still requires testing and treatment in its own right.
Other options, including vaginal DHEA and a non-hormonal oral medication, are available for some indications.
Safety and labeling
Evidence on breast cancer risk with local vaginal estrogen has been reassuring, though it derives largely from observational studies rather than long-term trials. Anyone with a personal history of breast cancer, particularly those taking an aromatase inhibitor, should make this decision with their oncology team.
Local vaginal estrogen historically carried a boxed warning applied to estrogen products broadly. The FDA began removing these boxed warnings in November 2025 and approved the first batch of revised labels in February 2026. The change applies to menopausal hormone therapy products generally, and labeling is being updated product by product.
When to seek medical advice
- Any bleeding after twelve consecutive period-free months, which is never explained by dryness alone
- Persistent vulvar itching, a white or thickened patch, a lump, an ulcer or a sore that does not heal, which can indicate lichen sclerosus or another condition needing different treatment
- Brown or blood-tinged discharge after menopause
- Symptoms of an active urinary tract infection, which need testing and treatment rather than estrogen alone
Common misconceptions
| Misconception | Truth |
|---|---|
| GSM resolves on its own. | It typically progresses without treatment, because the underlying tissue changes continue while estrogen remains low. |
| Local vaginal estrogen is the same as hormone therapy. | It acts locally with minimal systemic absorption and is a distinct treatment with a distinct risk profile. |
| Recurrent thrush explains the itching. | Persistent itching in menopause is frequently GSM or another vulvar condition, and repeated self-treatment for thrush delays the right diagnosis. |
Frequently asked questions
Genitourinary syndrome of menopause, the umbrella term for genital, sexual and urinary symptoms caused by falling estrogen, including vaginal dryness, painful sex, itching, urinary urgency and recurrent urinary tract infections.
No. Unlike hot flashes, which tend to ease over time, GSM typically progresses without treatment because the underlying tissue changes continue while estrogen remains low.
Lubricants reduce friction during sex and are used at the time. Moisturizers are used regularly, several times a week, to provide topical comfort. Many people use both.
Evidence to date has been reassuring, though it derives largely from observational studies rather than long-term trials. It acts locally with minimal absorption. Anyone with a breast cancer history should decide with their oncology team.
Yes. Recurrent urinary tract infections form part of GSM, and local vaginal estrogen has evidence for reducing recurrence. An active infection still needs testing and treatment separately.
It can. Thinner tissue and altered vaginal pH cause itching and burning. Persistent vulvar itching should be examined, since conditions such as lichen sclerosus need different treatment and monitoring.
Thinning and retraction of vulvar tissue forms part of GSM. Any persistent itching, white or thickened patch, lump or non-healing sore should be examined rather than assumed to be normal change.
Most often because of GSM: thinner, less elastic and less lubricated tissue. It is frequently treatable and is worth raising with a provider.
Yes, as vaginal pH and the local microbiome change. Brown or blood-tinged discharge is different and requires prompt assessment as postmenopausal bleeding.
Vulvovaginal atrophy and atrophic vaginitis. The terminology changed because those terms omitted the urinary component, which responds to the same treatment.
